Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Orexin (hypocretin) neuropeptides promote wakefulness by signaling through two G-protein coupled receptors, Orexin 1 Receptor (OX(1)R) and Orexin 2 Receptor (OX(2)R). MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia. In radioligand binding and functional cell based assays MK-6096 demonstrated potent binding and antagonism of both human OX(1)R and OX(2)R (<3 nM in binding, 11 nM in FLIPR), with no significant off-target activities against a panel of >170 receptors and enzymes. MK-6096 occupies 90% of human OX(2)Rs expressed in transgenic rats at a plasma concentration of 142 nM, and dose-dependently reduced locomotor activity and significantly increased sleep in rats (3-30 mg/kg) and dogs (0.25 and 0.5 mg/kg). DORA-22, an analog of MK-6096, exhibits similar sleep promoting properties that are absent OX(1/2)R double knockouts, demonstrating the mechanism of action and specificity of these effects. These findings with a novel, structurally distinct class of OxR antagonists provide further validation of the orexin pathway as an effective target to promote normal sleep. Comparative analysis of the biochemical and pharmacokinetic properties of these compounds relative to other OXR antagonists provides a basis for understanding the attributes critical for in vivo efficacy. This mechanism is distinct from current standard of care such that MK-6096 represents a novel and selective therapeutic for the treatment of insomnia. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
Neuroscience Department, Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA 19486, USA. christopher_winrow@merck.com
Christopher J
CJ
Winrow
Anthony L
AL
Gotter
Christopher D
CD
Cox
Pamela L
PL
Tannenbaum
Susan L
SL
Garson
Scott M
SM
Doran
Michael J
MJ
Breslin
John D
JD
Schreier
Steven V
SV
Fox
Charles M
CM
Harrell
Joanne
J
Stevens
Duane R
DR
Reiss
Donghui
D
Cui
Paul J
PJ
Coleman
John J
JJ
Renger
D000818:Animals; D004285:Dogs; D051379:Mice; D064446:Orexin Receptors; D010880:Piperidines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors*; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors*; D012890:Sleep / Q000187:drug effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*
C573816:MK-6096; D064446:Orexin Receptors; D010880:Piperidines; D011743:Pyrimidines; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide